Pfizer Inc. experienced a 3.9% decline in share price during extended trading, even as it reported a significant 27.06% earnings surprise in its last quarter. The pharmaceutical company has maintained an impressive four-quarter earnings surprise average of 19.79%, but its year-to-date stock performance shows a decline of 13.8%. With earnings per share expectations of $1.66 ahead of the May 3 report, analysts are closely watching Pfizer's market position, bolstered by its COVID-19 vaccine and a stable dividend yield of 3.3%.
“Shares of Pfizer · fell · as much as 3.9% in extended trading”
“Pfizer · developed · COVID-19 vaccine · two-dose shot in collaboration with Germany's BioNTech”
“Wyeth · was acquired by · Pfizer · over a decade ago”
“Pfizer · will report · first-quarter 2022 results · May 3”
“Pfizer · beat earnings expectations by · last reported quarter · 27.06%”
“Pfizer · exceeded earnings expectations in · last four quarters · true”
“Pfizer · has a four-quarter earnings surprise of · average · 19.79%”
“Pfizer’s stock · has declined · this year so far · 13.8%”
“Pfizer · sales contributors are likely to have been · direct sales and alliance revenues from BioNTech for COVID-19 vaccine · true”
“Pfizer · Earnings ESP is · 12.46% · negative”
“Pfizer · has a Zacks Rank · #3 · Hold”
“Pfizer · funds · development costs for Eliquis · 50% to 60%”
.svg&width=160)